Teriya Richmond
Family Medicine · Houston, TXNPI 1649413329
Payments from drug & device makers
Across 204 payments — averaging $2418.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$239K
- Myovant Sciences GmbH$105K
- Pfizer$60K
- AstraZeneca$55K
- Viiv Healthcare Company$24K
- Sagent Pharmaceuticals$7K
- plus $4K from 13 others
Across 12 payments — averaging $635.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$5K
- Viiv Healthcare Company$2K
What the payments were for
- Consulting fees$3,87559%
- Travel & lodging$1002%
- Food & beverage$2,46038%
- Education$1002%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 91 | $239,060 |
| Myovant Sciences GmbH | 40 | $105,134 |
| Pfizer | 12 | $60,013 |
| AstraZeneca | 7 | $54,542 |
| Viiv Healthcare Company | 19 | $23,645 |
| Sagent Pharmaceuticals | 3 | $7,419 |
| Lilly USA, LLC | 3 | $1,150 |
| Lupin Inc. | 7 | $999 |
| Gilead | 7 | $472 |
| Novartis | 4 | $361 |
| Johnson & Johnson | 1 | $113 |
| Therapeuticsmd, Inc. | 1 | $111 |
| Scynexis, Inc. | 1 | $109 |
| Janssen Products, LP | 1 | $100 |
| AbbVie | 3 | $64 |
| Novo Nordisk | 1 | $59 |
| Myovant Sciences Inc. | 1 | $25 |
| ERMI LLC | 1 | $22 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$493,411 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 25 | $7,157 |
| Gabapentin | 30 | $684 |
| Metformin Hcl | 20 | $457 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $389 |
| Alprazolam | 15 | $342 |
| Pantoprazole Sodium | 12 | $291 |
| Famotidine | 12 | $290 |
| Losartan Potassium | 31 | $277 |
| Allopurinol | 24 | $266 |
| Atorvastatin Calcium | 33 | $248 |
| Montelukast Sodium | 23 | $245 |
| Lisinopril | 11 | $232 |
| Levothyroxine Sodium | 16 | $177 |
| Amlodipine Besylate | 46 | $166 |
| Spironolactone | 13 | $160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $14 | $7,15725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Houston
- Lisa HollowayHouston$30.1M
- Veronica FragosoHouston$24.5M
- Bonnie ColvilleHouston$19.6M
- Oscar de ValleHouston$12.8M
- van TranHouston$11M
- Joe PouzarHouston$10.7M
- Aalia Al-BarwaniHouston$6.8M
- Terence ChangHouston$3.3M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.